Current evidence points to an important role of N-methyl-D-aspartate (NMDA) receptor activation in the pathogenesis of hypoglycemic neuronal death. MK-801 {dizocilpine maleate, (+ )-5-methyl-10,1l-dihydro-5H-di[a,d]cyclohepten-5, lO-imine} is an anticonvulsant compound also known to be a potent noncompetitive an tagonist at NMDA receptors, readily crossing the blood brain barrier after parenteral administration. Treatment of rats with dizocilpine (1.5-5.0 mg/kg) injected intrave nously during profound hypoglycemia (blood glucose lev els 1.5-2.0 mM) at the stage of B-wave (1-4 Hz) slowing of the EEG mitigated selective neuronal necrosis in the hip pocampus and striatum, assessed histologically after 1week survival. The degree of neuroprotection in the stri atum and in the CAl pyramidal cells of the hippocampus was dose dependent. Because of concern for a possible
Evidence has recently accumulated that hypogly cemia causes neuronal death in the brain not by simply and directly depriving neurons of glucose and energy. Rather, experimental results implicate activation of neuronal excitatory receptors (Auer et aI., 1985c) of the N-methyl-D-aspartate (NMDA) subtype (Wieloch, 1985) in mediating hypoglycemic neuronal death. One of the most potent, recently discovered (Cline schmidt et aI., 1982a) NMDA an tagonists is MK-801 (Wong et aI., 1986) . In addition to protecting against NMDA neurotoxicity (Foster et aI., 1987; Olney et aI., 1987) , MK-801 protects against hypoxic-ischemic neuronal injury when given either before (Gill et aI., 1987; McDonald et 270 hypothermic mechanism of brain protection by MK-801, core temperature was closely monitored and was found not to decrease significantly. Since CBF is normal or in creased in hypoglycemia, a fall in brain temperature dur ing hypoglycemia is unlikely to play a role in the mecha nism of the neuroprotection seen with the drug. The find ings indicate that in profound hypoglycemia, intravenous administration of the NMDA antagonist dizocilpine, even after the appearance of B-wave EEG slowing, can reduce the number of necrotic neurons in several brain regions and suggest that the neuroprotective effect of MK-801 is not related to hypothermia. Key Words: Brain damage Excitatory amino acid-Hypoglycemia-N-Methyl-D aspartate antagonist-MK-801 (dizocilpine)-Neuronal necrosis.
aI., 1987, Olney et aI., 1989a) or after (Gill et aI., 1988; Park et aI., 1988; Rod and Auer, 1989 ) the insult.
In tissue culture, cortical neurons are protected against glucose deprivation neuronal injury by MK-801 (Monyer et aI., 1989) . The present study was undertaken to test the efficacy in vivo of intrave nous administration of the potent NMDA antago nist dizocilpine (MK-80l) in protecting the major brain regions damaged by hypoglycemia. Because of results obtained in ischemia suggesting that MK-801 may be neuroprotective partly via an induced hypothermia (Buchan and Pulsinelli, 1990) , temper ature was closely monitored. The results demon strate a regional temperature-independent neuro protection by MK-801 in hypoglycemia in several brain regions.
MATERIALS AND METHODS
Male Wistar rats (Charles River, St. Constant, Quebec, Canada) weighing 222-466 g were fasted overnight with free access to tap water. Four groups of six rats were studied: Three treatment groups were given MK-801 {di zocilpine]maleate, (+ )-5-methyl-1O, ll-dihydro-5H-di [a,d] cyclohepten-5,IO-imine} in intravenous doses of 1.5, 2.8, and 5.0 mg/kg, injected during the B-wave (1-4 Hz) stage of EEG slowing; control rats were given intrave nous saline.
The detailed description of the hypoglycemia model used can be found in a previous publication (Auer et al., 1984a) . Briefly, rats were given 10-15 IV/kg i.p. regular insulin, and after 45 min were anesthetized in 3.0% halo thane, intubated, and ventilated with 1.0% halothane in a 2:1 N20/02 mixture. A tail vein and tail artery were can nulated, allowing suxamethonium paralysis and continu ous blood pressure (BP) recording, respectively. The BP was automatically recorded onto a computer disk every 6 s. Arterial blood glucose levels, pH, Pc02, and P02 were monitored. A heparinized central venous catheter was inserted via the right jugular vein for the purpose of con trolling the BP by withdrawal or reinfusion of the blood as required. A homeothermic heating blanket system with a rectal thermistor probe maintained the core temperature at 37-38°C. The bipolar interhemispheric EEG was digi tized on a computer in real time, representative 5-s strips being regularly stored.
After surgery, the halothane was discontinued and electrocerebral silence was awaited. During the stage of high-amplitude slowing of the EEG to the B-range (blood glucose levels in the range of 1.5-2.0 mM or 27-36 mg/100 ml), the rats were given intravenously either normal sa line or dizocilpine in the above doses. Following 30 min of electrocerebral silence, 1. 0 ml of 25% glucose was given by hand over 2 min, followed by 25% glucose infusion at a rate (0.056--0.078 mlImin) such that blood glucose levels rapidly ascended to a plateau between 5. 6 and 10.5 mM.
When the rats began to awaken, they were taken off the ventilator, extubated, returned to their cages, and given oxygen and intravenous glucose for 10-12 h post surgical recovery.
At 1 week of survival, trans cardiac perfusion-fixation with phosphate-buffered 4% formaldehyde was done un der 3.0% halothane in 2:1 N20/02• The brains were re moved, processed in graded alcohols, embedded in par affi n, sub serially sectioned at 200-lLm intervals at a thick-ness of 8 ILm, and double-stained with 1 % acid fuchsin and 0. 1 % cresyl violet. The quantification of neuronal necro sis was carried out blindly by direct visual counting of acidophilic neurons under the microscope. Such neurons were known from previous work in hypoglycemia to be irreversibly damaged or necrotic (Auer et al., 1985a) . Brain damage was graded according to the degree of se lective neuronal necrosis, as infarcts were uniformly ab sent. In the cerebral cortex, animals were rated according to the number of necrotic neurons per section, at the coronal leval of the subfornical organ, into the following grades of damage: <10 necrotic cells, 10-100 necrotic cells, 100-1,000 necrotic cells, and >1,000 necrotic cells.
In the hippocampus, where total cell counts were avail able from previous quantitative studies (Auer et al. , 1984a) , the percentage neuronal necrosis in the dentate gyrus and CAl pyramidal cells was calculated at each level of the hippocampus along its septotemporal axis. Last, in the caudate nucleus, two laterally located 500-lLm microscopic fields, representing the most damaged area of the rat striatum in hypoglycemia (Auer et al. , 1984b) , were counted and the percentage neuronal necrosis cal culated.
For comparing the percentages of neuronal necrosis between groups, the arcsine transformation was per formed (Zar, 1974) , to permit subsequent parametric anal ysis using a one-way analysis of variance with Dunnett's t test. The core temperatures measured were compared by analysis of variance. Finally, in comparing the number of damaged and undamaged hemispheres with controls, Fisher's exact probability was calculated.
RESULTS
Physiologic parameters showed no significant dif ferences between the groups, apart from mild hy pertension (Table 1) in the MK-801-treated groups. This was likely due to the sympathomimetic action of MK-801 (Cline schmidt et aI., 1982b). A significant clinical difference was seen between the untreated rats and the rats treated with dizo cilpine. All three doses of MK-801 produced a cat- (n = 6, all groups). Percentages were transformed according to the standard arcsine transformation (Zar, 1974) (Whishaw and Auer, 1989 ). They did not respond to pain and could not be roused from this state. The catalepsy graduaJly subsided over the course of the first 2-3 days after the administra tion of MK-801 (Whishaw and Auer, 1989) . Control rats were sluggish during this time period, but were otherwise normal. NeuropathologicaJly, MK-801 decreased hypo glycemic brain damage in the hippocampus and stri atum, but not the cortex. The mitigation of damage in the CAl sector was dose dependent (Fig. O. His tologicaJly, the reduction in neuronal necrosis in the CAl pyramidal ceJl band was striking (Fig. 2) . In the dentate gyrus, all three doses of MK-801 mitigated neuronal death (Fig. 3) , but the dose dependency of the protective effect seen in the CAl zone was not observed. Nevertheless, the characteristic neuronal A -..
;z necrosis in the dentate granule cell band, also seen in human cases of hypoglycemia (Auer et aI., 1989) , was frequently eliminated entirely (Fig. 4) .
In the lateral caudate nucleus, neuronal necrosis was strikingly reduced from 75% of the neuronal population to < 10% in animals treated with 5 mg/kg of MK-801 ( Fig. 5 ). Complete histologic protection against neuronal necrosis was commonly seen at this dose of dizocilpine (Fig. 6) .
The cortex showed significant protection only in the group receiving 2.8 mg/kg of MK-801 ( Fig. 7) . No vacuolation or other changes suggestive of a histotoxic effect of MK-801 were seen in neurons of the retrosplenial or cingulate cortex (Olney et aI., 1989b) .
To examine the possibility that dizocilpine acts by a hypothermic mechanism, the continuously monitored core temperature was examined care fuJly in all four groups. All animals had a slight de crease in core body temperature at the onset of EEG isoelectricity (Fig. 8) , but there was no corre lation between the dose of MK-801 and the magni tude of the temperature decrease. The only group in which the body temperature was significantly lower than control was the 1.5-mg/kg group (p < 0.01), the group showing the least robust neuroprotection his tologically.
DISCUSSION
The most recent significant advance in the study of brain damage due to low blood sugar has been the new understanding that hypoglycemic neuronal death is mediated by excitatory receptors (Auer et aI., 1985c; Wieloch, 1985) . The subtype of excitato ry neuronal receptor involved is named after its most favored agonist, NMDA, evidenced by the according to the standard arcsine transformation (Zar, 1974) to allow one-way analysis of variance with Dunnett's t test. *p < 0.05; **p < 0.01.
demonstration that hypoglycemic neuronal damage can be reduced by intracerebral injection of the spe cific NMDA antagonist aminophosphonohep tanoate (Wieloch, 1985) . The fact that neurons die via a receptor-mediated process, rather than by glu cose starvation and energy failure per se, allows therapeutic intervention using appropriate receptor antagonists. The present findings indicate that neu ronal necrosis in the brain may be reduced by in travenous administration of the centrally penetrat ing NMDA antagonist MK-801 at the stage of pro found hypoglycemia accompanied by a-wave slowing of the EEG, even if coma (isoelectric EEG, electrocerebral silence) ensues. MK-801 is currently the most potent NMDA re ceptor antagonist known. The compound was first A described in 1982 to have anticonvulsant, sympa thomimetic, and anxiolytic activity (Clineschmidt et aI., 1982a-c) . Being a substituted dibenzocyclohep tenimine derivative, it readily crosses the blood brain barrier, raising the attractive clinical pos sibility of parenteral administration. A single intravenous dose of MK-801 in the rat causes neu robehavioral changes lasting 2-4 days (Whishaw and Auer, 1989) , in spite of a plasma half-life of only 1 h (Hucker et aI., 1983; Scheller et aI., 1989) . This probably relates to the very slow exit of the mole cule from the NMDA receptor-associated ion chan nel (Huettner and Bean, 1988) . Reversible neuronal vacuolation has been reported several hours after MK-801 administration, probably related to tempo rary sublethal cellular perturbations associated with a phencyclidine agonist effect (Olney et aI., 1989b) . MK-801 binds with great affinity to isolated brain fractions (Wong et aI., 1986 (Wong et aI., , 1988 McKernan et aI., 1989) , and a high density of binding has been shown in the hippocampus, amygdala, entorhinal cortex, and neocortex of the rodent (Bowery et aI., 1988) and human (Kornhuber et aI., 1989) brain. Physio logically, MK-801 effectively blocks NMDA recep tor-mediated processes in the hippocampus (Coan et aI., 1987) , a region of high NMDA receptor den sity (Greenamyre et aI., 1985; Monaghan et aI., 1985) . Thus, anatomic, physiologic, and pharmaco logic evidence indicates MK-801 is a specific and potent NMDA antagonist in the brain regions dam aged by hypoglycemia.
These results, taken together with the finding in culture that MK-801 protects against glucose depri vation neuronal injury (Monyer et aI., 1989) , sug- on the right of each photomicrograph, with the medial portion of the internal and external blades in the superior and inferior portion. Necrotic neurons have pyknotic, shrunken nuclei, seen in the crest and outer blade of the untreated rat 1 week after 30 min of cerebral EEG isoelectricity due to profound hypoglycemia. The typical rat treated with 5 mg/kg i.v. MK-801 shows essentially no neuronal necrosis at a comparable septotemporal level of the hippocampus, although a few high-dose rats did show a few necrotic neurons in the dentate. 0.1% cresyl violet and 1% acid fuchsin. Bars, 125 j-Lm. Percentage (means ± SEM) neuronal necrosis in the caudate nucleus following injections of MK-801 (n = 6, all groups). Percentages were transformed by the standard arc sine transformation (Zar, 1974) to allow one-way analysis of variance with Dunnett's t test. 'p < 0.05 ; "p < 0.01. gest a neuroprotective mechanism dependent on NMDA receptor blockade. Results in hypoxia ischemia, a related excitotoxic neuronal pathology (Rothman and Olney, 1986; Auer and Siesjo, 1988) , have shown that pretreatment with MK-801 reduces structural brain damage (Gill et aI., 1987; McDonald et aI., 1987; Ozyurt et aI., 1988) . MK-801 is even effective when administered in the recovery period after restoration of blood supply to the brain (Gill et aI., 1988; Park et aI., 1988; Rod and Auer, 1989) . The reason for this success in postischemic admin istration of MK-801 may relate both to the delayed neuronal death (Kirino, 1982) seen after ischemia and to the fact that MK-801 actually blocks the ion channel subsequently activated by the NMDA ago nist (Foster and Wong, 1987; Huettner and Bean, 1988) . A comparable delayed neuronal death is not seen after hypoglycemia, where neuronal necrosis occurs within a few hours of the insult (Auer et aI., 1985a,b) . However, further studies are necessary to A determine whether parenteral MK-801 is effective when administered at later stages of profound hy poglycemia, i.e., when cerebral isoelectricity and coma have already occurred.
Because some temperature dependence of isch emic neuroprotection by MK-801 has been found (Buchan and Pulsinelli, 1990) and because even small degrees of intraischemic (Busto et aI., 1987) and postischemic (Busto et aI., 1989) hypothermia are known to be protective against hypoxic-isch emic neuronal necrosis, it may be questioned whether MK-801 exerts its protective effect via an induced hypothermia. Temperature may affect NMDA blockade by MK-801 (Davies et aI., 1988) . To address this question, body temperature was monitored continuously in this study and was found to fall only slightly at the onset of electrocerebral silence. This fall in body temperature was signifi cant only in the 1.8-mg/kg group, where the smallest neuroprotective effect was seen. Furthermore, since the brain is well perfused during hypoglyce mia (Abdul-Rahman et aI., 1980) , brain temperature would be expected to be at or near body core tem perature. Thus, since body temperature did not fall significantly in the groups most protected by MK-801, the findings of the present study argue strongly against a hypothermic mechanism of action to ex plain the neuroprotection seen with MK-801.
MK-801 augments glucose utilization in the hip pocampus, diencephalon, and posterior cingulate cortex of conscious rats (Nehls et aI., 1988) . Al though stimulation of glucose utilization might seem a plausible alternative mechanism for the neuropro tection seen in hypoglycemia, the distribution of MK-801-induced augmentation of glucose utiliza tion does not correlate with the distribution of neu roprotection. Furthermore, any MK-801-induced enhancement in the ability of the brain to utilize glucose during hypoglycemia should have been manifest as a delay in the onset of EEG silence in the MK-801-treated groups. This argues against any MK-801-induced augmentation of glucose utiliza tion as a mechanism of neuroprotection in hypogly cemia. The identity of the endogenously produced brain excitotoxin causing hypoglycemic neuronal necro sis has not been established. Hypoglycemia causes a marked increase in levels of aspartate in whole brain tissue (Agardh et aI., 1981) and in the extra cellular space (Sandberg et aI., 1986) where neuro nal receptors are exposed to the high local concen trations. Brain extracellular glutamate levels are also increased in hypoglycemia, but to a lesser de gree than aspartate (Sandberg et aI., 1986 Recordings were taken at 30-min intervals from 3 h prior to isoelectricity to a maximum of 3 h of recovery. Only the tem perature fall in the 1.5-mg/kg group was significantly differ ent from control, and only at one point in time, the onset of isoelectricity. One-way analysis of variance with Dunnett's t test. *p < 0.05. et aI., 1987). These findings make aspartic acid an attractive candidate for the pathogenesis of hypo glycemic neuronal necrosis. Aspartate and gluta mate are both agonists at all three subtypes of ex citatory amino acid receptor, and it may be that concomitant blockade at non-NMDA sites could give a more robust protective effect than NMDA blockade alone (Frandsen et aI., 1989) .
